New Diabetes Guidelines: Impact on Eligibility for Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Canada
Authors:
- 16 April 2022
- journal article
- research article
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 46 (7) , 691-698
Abstract
No abstract availableKeywords
Funding Information
- University Hospital Foundation
- University of Alberta Faculty of Medicine and Dentistry
- Novo Nordisk
- Diabetes Action Canada
This publication has 30 references indexed in Scilit:
- Impact of the Diabetes Canada Guideline Dissemination Strategy on the Prescription of Vascular Protective Medications: A Retrospective Cohort Study, 2010–2015Diabetes Care, 2018
- Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based studyBMJ, 2018
- Data Resource Profile: National electronic medical record data from the Canadian Primary Care Sentinel Surveillance Network (CPCSSN)International Journal of Epidemiology, 2017
- Pharmacologic Management of Type 2 Diabetes: 2016 Interim UpdateCanadian Journal of Diabetes, 2016
- Representativeness of patients and providers in the Canadian Primary Care Sentinel Surveillance Network: a cross-sectional studyCMAJ Open, 2016
- Validity of Diagnostic Codes for Acute Stroke in Administrative Databases: A Systematic ReviewPLOS ONE, 2015
- Validating the 8 CPCSSN Case Definitions for Chronic Disease Surveillance in a Primary Care Database of Electronic Health RecordsThe Annals of Family Medicine, 2014
- Prevalence and Epidemiology of Diabetes in Canadian Primary Care Practices: A Report from the Canadian Primary Care Sentinel Surveillance NetworkCanadian Journal of Diabetes, 2014
- Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: systematic review and meta-analysisBMJ, 2013
- Sulfonylurea Compounds Uncouple the Glucose Dependence of the Insulinotropic Effect of Glucagon-Like Peptide 1Diabetes, 2007